Drug Trial Radar · NCT04148963
A Study of Staccato Loxapine (ADASUVE®) for Inhalation
Last checked: Nov 20, 2026Latest source record: Nov 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
150
Planned (sponsor's estimate)
Start
Dec 1, 2019
Primary completion
May 1, 2020
Study completion Aug 1, 2020
Sponsor
- Lead sponsor
- Lee's Pharmaceutical LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic or bipolar disorder patients.
Conditions
- Psychomotor Agitation
- Schizophrenia
- Bipolar Disorder
Interventions
Inhaled loxapineDrug
Inhaled Loxapine 9.1 mg, may repeat x 1 or 2 after 2 hours
Inhaled placeboDrug
Inhaled placebo, may repeat x 1 or 2 after 2 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in PANSS-EC From BaselineTime frame: Time Frame: Baseline and 2 hours
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.